2 completed, 2 recruiting. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Recruiting 2 |
| Phase 2 | 1 | Completed 1 |
Follow VX-561: new trials by email Literature Review of VX-561 trials Research Report on VX-561
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants VX-272, Placebo, Tezacaftor - Cystic Fibrosis | Phase 1 | Recruiting | Vertex Pharmaceuticals Incorporated | 160 | 2026-02-25 | 2026-09-23 |
| Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis VX-581, Placebo, D-IVA - Cystic Fibrosis | Phase 1 | Recruiting | Vertex Pharmaceuticals Incorporated | 152 | 2025-12-09 | 2026-10-19 |
| Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis VX-828, Placebo, Itraconazole - Cystic Fibrosis | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 165 | 2023-12-12 | 2026-08-10 |
| A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis IVA, TEZ/IVA, VX-445 - Cystic Fibrosis | Phase 1 / Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 225 | 2017-01-23 | 2022-01-18 |
Cystic Fibrosis (4)
Vertex Pharmaceuticals Incorporated (4)
United States (4) · Australia (1) · Belgium (1) · Netherlands (1)
PMID 30334692, PMID 33331662, PMID 37983082
2017 (1)